ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MOR107
Previous Study | Return to List | Next Study

First in Human Single Ascending Dose Study of MOR107

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03067363
Recruitment Status : Terminated (Part 1 completed successfully. Part 2 not conducted.)
First Posted : March 1, 2017
Last Update Posted : February 7, 2018
Sponsor:
Collaborator:
Quotient Clinical
Information provided by (Responsible Party):
Alan Richardson, LanthioPep BV

Brief Summary:
This is the first in human study of MOR107. It is a 2 part, single centre, double-blind, randomised, placebo-controlled study in healthy male subjects. Part 1 is a single ascending dose study, and Part 2 is a parallel group, dose range finding study in healthy male subjects on a low sodium diet.

Condition or disease Intervention/treatment Phase
Safety Drug: MOR107 Drug: Placebo Other: Low sodium diet Phase 1

Detailed Description:

MOR107 is an angiotensin 2 receptor (AT2R) agonist with the potential to treat a wide range of diseases through activation of the protective arm of the renin-angiotensin system.

In this study MOR107 will be administered to humans for the first time.

The study will enroll healthy male subjects and is split into two sequential parts, both of which have a single centre, double-blind, randomised, placebo-controlled design.

Part 1 will evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of MOR107.

Part 2 will evaluate the pharmacodynamics, safety, tolerability and PK of three different doses of MOR107 in healthy male subjects who will be fed a low sodium diet in order to increase AT2R expression.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Part 1: single ascending doses Part 2: parallel group
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet
Actual Study Start Date : February 16, 2017
Actual Primary Completion Date : March 23, 2017
Actual Study Completion Date : March 23, 2017

Arm Intervention/treatment
Experimental: Part 1, MOR107 Dose level 1
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Experimental: Part 1, MOR107 Dose level 2
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Experimental: Part 1, MOR107 Dose level 3
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Experimental: Part 1, MOR107 Dose level 4
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Experimental: Part 1, MOR107 Dose level 5
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Experimental: Part 1, MOR107 Dose level 6
MOR107, single subcutaneous injection
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Placebo Comparator: Part 1, Placebo
Placebo, single subcutaneous injection
Drug: Placebo
Solution for injection manufactured to match MOR107 solution for injection
Other Name: Placebo (for MOR107)

Experimental: Part 2: MOR107 low dose
MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Other: Low sodium diet
Diet designed to restrict sodium intake to 40 mmol/day

Experimental: Part 2: MOR107 medium dose
MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Other: Low sodium diet
Diet designed to restrict sodium intake to 40 mmol/day

Experimental: Part 2: MOR107 high dose
MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
Drug: MOR107
MOR107 solution for injection
Other Name: LP2-3

Other: Low sodium diet
Diet designed to restrict sodium intake to 40 mmol/day

Placebo Comparator: Part 2: Placebo
Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
Drug: Placebo
Solution for injection manufactured to match MOR107 solution for injection
Other Name: Placebo (for MOR107)

Other: Low sodium diet
Diet designed to restrict sodium intake to 40 mmol/day




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (safety and tolerability) [ Time Frame: Up to 10 days post-dose ]
    Reporting of adverse events, physical examination, injection site assessment, vital signs, ECG, and clinical chemistry, haematology and urinalysis


Secondary Outcome Measures :
  1. Time from dosing at which the maximum MOR107 concentration was observed (Tmax) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  2. Maximum observed MOR107 concentration (Cmax) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  3. Concentration of MOR107 at 12 hours post-dose (C12) [ Time Frame: 12 hours post-dose ]
    Plasma PK parameter

  4. Concentration of MOR107 at 24 hours post-dose (C24) [ Time Frame: 24 hours post-dose ]
    Plasma PK parameter

  5. Area under the curve from 0 time to last measurable MOR107 concentration (AUC0-t) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  6. Area under the curve from 0 time to infinity for MOR107 (AUC0-inf) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  7. Percentage of AUC(0-inf) for MOR107 extrapolated beyond last measured time point (AUC%extrap) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  8. Slope of the apparent elimination phase for MOR107 (Lambda-z) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  9. Apparent elimination half-life for MOR107 (T-half) [ Time Frame: Up 48 hours post-dose ]
    Plasma PK parameter

  10. MOR107 Cmax normalised for dose (Cmax/D) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  11. MOR107 AUC(0-t) normalised for dose (AUC[0-t]/D) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  12. MOR107 AUC(0-inf) normalised for dose (AUC[0-inf]/D) [ Time Frame: Up to 48 hours post-dose ]
    Plasma PK parameter

  13. Amount of MOR107 excreted in the urine over a specified period of time after dosing (Ae) [ Time Frame: Up to 48 hours post-dose ]
    Urine PK parameter

  14. Cumulative amount of MOR107 excreted in the urine (CumAe) [ Time Frame: Up to 48 hours post-dose ]
    Urine PK parameter

  15. Amount of MOR107 excreted in the urine over a specified period of time after dosing, expressed as a percentage of the administered dose (Ae%) [ Time Frame: Up to 48 hours post-dose ]
    Urine PK parameter

  16. Cumulative amount of MOR107 excreted in the urine, expressed as a percentage of the administered dose (CumAe%) [ Time Frame: Up to 48 hours post-dose ]
    Urine PK parameter

  17. Renal clearance: the apparent volume of plasma cleared per unit time via renal elimination (CLr) [ Time Frame: Up to 48 hours post-dose ]
    Urine PK parameter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  1. Healthy males
  2. Age 18 to 45 years of age
  3. Body mass index of 18.0 to 32.0 kg/m2
  4. For Part 2, subjects must have at least a 25% reduction in 24 hour urinary sodium excretion on Day -2 compared with admission

Key Exclusion Criteria:

  1. Subjects who have received any IMP in a clinical research study within the previous three months
  2. Regular alcohol consumption >21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  3. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening/admission
  4. Current smokers of e-cigarettes and nicotine replacement products and those who have smoked these products within the last 12 months
  5. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
  6. Positive drugs of abuse test result
  7. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  8. History of psychiatric disorder, cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator
  9. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03067363


Locations
United Kingdom
Quotient Clinical
Nottingham, Nottinghamshire, United Kingdom, NG11 6JS
Sponsors and Collaborators
Alan Richardson
Quotient Clinical
Investigators
Study Director: Axel Mescheder, MD LanthioPep BV

Responsible Party: Alan Richardson, Clinical Project Manager, LanthioPep BV
ClinicalTrials.gov Identifier: NCT03067363     History of Changes
Other Study ID Numbers: MOR107-C001
First Posted: March 1, 2017    Key Record Dates
Last Update Posted: February 7, 2018
Last Verified: February 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No